Suchen
PDS Biotechnology Corp
PDSBZur Watchlist hinzufügen
1.020USD
-0.045-4.23%
Handelsschluss 10-08 16:00（ET）
57.04MMarktkapitalisierung
VerlustKGV TTM
Nachbörsliches Trading 18:49 (ET)1.020USD-0.020-1.92%
Nachbörsliches Trading 18:49 (ET)Über PDS Biotechnology Corp Unternehmen
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
PDS Biotechnology Corp Profil
BörsenkürzelPDSB
Name des UnternehmensPDS Biotechnology Corp
IPO-datumOct 01, 2015
CEOBedu-Addo (Frank)
Anzahl der mitarbeiter24
WertpapierartOrdinary Share
GeschäftsjahresendeOct 01
Addresse303A College Road East
StadtPRINCETON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl08540
Telefon18002083343
Websitehttps://www.pdsbiotech.com
BörsenkürzelPDSB
IPO-datumOct 01, 2015
CEOBedu-Addo (Frank)
Führungskräfte von PDS Biotechnology Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Interim Principal Financial Officer, Director
President, Chief Executive Officer, Interim Principal Financial Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Gregory L. Conn, Ph.D.
Dr. Gregory L. Conn, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Janetta Trochimiuk
Ms. Janetta Trochimiuk
Interim Principal Accounting Officer
Interim Principal Accounting Officer
--
--
Dr. Ilian Petkov Iliev, Ph.D.
Dr. Ilian Petkov Iliev, Ph.D.
Independent Director
Independent Director
--
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
--
--
Mr. Spencer Brown
Mr. Spencer Brown
Senior Vice President, General Counsel, Corporate Secretary and Compliance Officer
Senior Vice President, General Counsel, Corporate Secretary and Compliance Officer
--
--
Mr. Lars Boesgaard
Mr. Lars Boesgaard
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Interim Principal Financial Officer, Director
President, Chief Executive Officer, Interim Principal Financial Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Gregory L. Conn, Ph.D.
Dr. Gregory L. Conn, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Janetta Trochimiuk
Ms. Janetta Trochimiuk
Interim Principal Accounting Officer
Interim Principal Accounting Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von PDS Biotechnology Corp?
Die fünf größten Anteilseigner von PDS Biotechnology Corp sind: Dr. Frank Bedu-Addo, Ph.D.
Wie viele Institutionen halten Anteile an PDS Biotechnology Corp (PDSB)?
Mit Stand vom 2026Q1 halten 167 Institutionen Anteile an PDS Biotechnology Corp, mit einem Gesamtmarktwert von etwa 9.62M, was 17.24% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 2078771.00 gestiegen.